Subscribe To

Price Alert Latest News Economic Calendar News

RARE / Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Read More

Demo Live Account See Partner Details

Content Topics

Ultragenyx

RARE

Reports

Loss

Tops

Revenue

Estimates

rare

Stock

Posted: Feb 16 2023, 18:49

Author Name: Zacks Investment Research

RARE News

By Seeking Alpha
November 2, 2023

Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript

Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Joshua Higa - Vice Pr

By Zacks Investment Research
October 17, 2023

Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisi

By Zacks Investment Research
September 8, 2023

Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t

By Reuters
August 10, 2023

Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line

The estate of Henrietta Lacks filed a lawsuit in Maryland federal court on Thursday accusing biopharmaceutical company Ultragenyx Pharmaceutical of un

By Zacks Investment Research
August 4, 2023

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track

By Zacks Investment Research
August 3, 2023

Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2023, it might be worth consid

By GlobeNewsWire
July 27, 2023

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developmen

By Zacks Investment Research
July 7, 2023

Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients wit

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.